跳至主要内容
临床试验/JPRN-UMIN000024063
JPRN-UMIN000024063已完成未知

Effect of Feru-guard 100M on the progression prevention of mild cognitive impairment associated - Effect of Feru-guard

Glovia Co., Ltd.0 个研究点目标入组 140 人开始时间: 2016年9月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
49years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients who have merged the neurodegenerative disease which presents a dementia-like symptoms, or there is a suspicion Parkinson's disease, Huntington's disease, Down's syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, cortical basal degeneration, etc. 2. patient suspected failure in cognitive function due to causes of the following Vascular dementia, metabolic diseases (hypothyroidism, vitamin B12 hypothyroidism, folic acid deficiency, etc.), head trauma, normal pressure hydrocephalus 3. Patients with delirium due to drug addiction Patients 4. there is a history of the following disease onset before Alcoholism, stroke, depression, manic state, schizophrenia 5. malignant neoplasm, patients with acute inflammatory disease 6. Patients have experience taking Feru-guard in the past 7. Patients have medication anti-dementia drugs 8. CDR-J 1 or more 9. HbA1c 8.0 or higher 10. If clear metabolic syndrome 11. Other 12. If the principal investigator or researcher has determined that improper participation in the present study

研究者

相似试验